Sigma-Proligo expands into Genopole d'Evry Biopark
Sigma-Proligo, a division of the Sigma-Aldrich group has acquired 2,000m2 of office space in the heart of the Genopole d'Evry biopark in the region of Paris.
Sigma-Proligo, a division of the Sigma-Aldrich group has acquired 2,000m2 of office space in the heart of the Genopole d'Evry biopark in the region of Paris.
With 65 employees in France, the majority of whom are researchers, Sigma-Proligo has world-class expertise in nucleic acid synthesis and holds several key patents in siRNA gene silencing technology. Thanks to an r&d team, which is also based in Evry, this site is expected to become a center of excellence within the Sigma-Aldrich group.
The new facility is expected to provide the capacity needed for the company to advance the production of high-quality oligonucleotides to meet emerging needs within the bioscience research sector.
'The biotech. image of Genopole, as well as the offices and working environment perfectly adapted to our operations, have been the main reasons behind our expansion into Evry,' said Khalil Arar, operations manager of Sigma-Aldrich Evry. 'The RNAi market has a predicted compound annual growth rate of 14%, and these new facilities are expected to provide Sigma-Proligo with the capacity to meet the increasing market demand for RNAi products.'